×
For more information, get in touch with our team:
+44 7918 53 08 73
Hint mode is switched on Switch off
For swift navigation between sections

Domestic bonds: Ligand, 0.75% 15may2023, USD (Conv.)
US53220KAF57

DATA PLATFORM FOR FINANCIAL MARKET PROFESSIONALS AND INVESTORS
  • High performance interface for global bond market screening
  • Full information on close to 500,000 bonds from 180 countries
  • 100% coverage of Eurobonds worldwide
  • Over 300 primary sources of prices
  • Ratings data from all international and local ratings agencies
  • Stock market data from 100 world trading floors
  • Intuitive, high speed user interface
  • Data access via the website, mobile application and add-in for Microsoft Excel

Trading chart

Stock exchange selection
Stock exchange selection
More about Cbonds Estimation
Data display in a chart | table
Data display in a chart | table
Work with the chart: switching the price, period, issue comparison
Work with the chart: switching the price, period, issue comparison
Download the chart in a convenient format
Customize fields in the table
Found: {{ graphTablePointsTotal }}
Show all fields
* Data is not available within the selected subscription
Latest data on
Quotes from market participants are indicative

Stock exchange and OTC quotes

Issue information

Profile
Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring assets. The Company’s technology portfolio CAPTISOL is a formulation technology that has enabled five Food and Drug ...
Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring assets. The Company’s technology portfolio CAPTISOL is a formulation technology that has enabled five Food and Drug Administration (FDA) approved products, including Pfizer’s VFEND IV and Baxter International’s Nexterone and is being used in a number of clinical-stage partner programs. The therapies in its portfolio in development address the unmet medical needs of patients for a spectrum of diseases, including hepatitis, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, asthma, rheumatoid arthritis and osteoporosis. It’s wholly owned subsidiaries include Ligand JVR, Allergan Ligand Retinoid Therapeutics, Seragen, Inc., Pharmacopeia, LLC, Neurogen Corporation, CyDex Pharmaceuticals, Inc. and Metabasis Therapeutics. 
  • Issuer
    Go to the issuer page
    Ligand
  • Full issuer name
    Ligand Pharmaceuticals, Inc
  • Sector
    corporate
  • Industry
    Healthсare
  • Stocks
Volume
  • Placement amount
    750,000,000 USD
  • Outstanding amount
    515,560,000 USD
  • Outstanding face value amount
    515,560,000 USD
Nominal
  • Nominal
    1,000 USD
  • Outstanding face value
    *** USD
  • Par amount, integral multiple
    *** USD

Cash flow parameters

  • Reference rate
    ***
  • Coupon Rate
    ***
  • Day count fraction
    ***
  • Interest Accrual Date
    ***
  • Coupon frequency
    *** time(s) per year
  • Payment currency
    ***
  • Delay days
    *** days
  • Maturity date
    ***
  • Early redemption date
    ***

Cash flow

Early redemption terms

***

DATA PLATFORM FOR FINANCIAL MARKET PROFESSIONALS AND INVESTORS
  • High performance interface for global bond market screening
  • Full information on close to 500,000 bonds from 180 countries
  • 100% coverage of Eurobonds worldwide
  • Over 300 primary sources of prices
  • Ratings data from all international and local ratings agencies
  • Stock market data from 100 world trading floors
  • Intuitive, high speed user interface
  • Data access via the website, mobile application and add-in for Microsoft Excel

Placement

  • Placement method
    Open subscription
  • Placement type
    Public
  • Order book
    *** (***) - *** (***)
  • Coupon (Yield) Guidance
    ***% - ***% (*** - ***%)
  • Placement
    *** - ***
  • Initial issue price (yield)
    (***%)
  • Bids
    *** USD
  • Number of bids
    ***
  • Geographic breakdown
    ***
  • Investor breakdown
    ***
  • Listing
    ***
Participants
  • Bookrunner
    ***

Conversion and exchange

Additional information

***

Latest issues

Identifiers

  • Registration
    ***
  • Date of program registration
    ***
  • ISIN
    ***
  • CUSIP
    ***
  • CUSIP 144A
    ***
  • CFI
    DCFNGR
  • FIGI
    BBG00KXRV5J3
  • WKN
    A2R2PG
  • SEDOL
    1905640
  • Ticker
    LGND 0.75 05/15/23
  • Type of security by CBR
    ***

Bond classification

  • Senior Unsecured
  • Registered
  • Coupon bonds
  • Convertible
  • Trace-eligible
  • Amortization
  • Callable
  • CDO
  • Dual currency bonds
  • Floating rate
  • For qualified investors (CIS region)
  • Foreign bonds
  • Green bonds
  • Indexed
  • Supranational bond issues
  • Mortgage bonds
  • Perpetual
  • Payment-in-kind
  • Non-Marketable Securities
  • Redemption Linked
  • Restructuring
  • Retail bonds
  • Covered
  • Securitization
  • Structured product
  • Subordinated
  • Sukuk

Restructuring

***

***

Holders